A new kind of treatment delivers a radioactive payload directly to the infectious bacteria within the body.
Breaking News April 5, 2022
Will there be a nuclear war? The eyes of the world are transfixed upon Russia and the Ukraine, and to some degree the provocation by the United States. People are unaware of a stealth nuclear attack being planned. The military has studied what makes people fear more a Mass Casualty Incident (MCI) or decapitation. They found decapitation is a much more fearful event because it “up close and personal.” Using this model, a new type of “treatment” is underway to deliver a radioactive “payload” directly into your body to fight infectious bacteria in lieu of antibiotics. This new radioactive treatment will bring nuclear war not in some distant land or a mushroom cloud on the horizon, but beamed directly into your body.
Under the auspices of One Health, we have been conditioned to believe that bacteria have become drug resistant. Many of the drug resistant infections, Tuberculosis, Pneumonia, Meningitis, Flesh-Eating Disease—all potentially fatal, are not something that you get in your home but rather are acquired in hospitals when you visit a physician or have a surgery. New antibiotics have been slow to come to market due to regulation and the new emphasis on medications as tools to influence Direct and Experiment Evolution.
The new radioactive payload treatment uses the cancer treatment model thereby killing infection with irradiation. Unlike a targeted antibiotic drug that kills the bacteria but leaves human cells unharmed this type of radiation is an indiscriminate short-range killer. Radioactive treatment is cytotoxic, poison to your cells, but it is the belief of the developers that your body can handle the cell death die-off.
The key to making this treatment “effective” is threefold according to the developers:
- First, you need a suitable radioisotope to emit sufficient radiation hopefully to become inert before it does too much collateral damage.
- You need a delivery system that will rapidly home in on the bacteria. In most people the infection is not localized but throughout their whole body.
- Lastly, you need a chemical agent to attach, binding or locking, one to the other.
This radioactive treatment is being conducted on the bacteria Y. pestis, the plague by scientists at the Los Alamos who develops radioisotopes for medical therapy. Other therapies, such as cART, use radioimmunotherapy (RIT) on antigen-specific monoclonal antibodies (mAbs) for targeted delivery of lethal doses of ionizing radiation to cells to treat HIV. LINK
The Antibody Radioisotope System
Actinium-225 appears to be the favored isotope as supposedly has a ten-day half-life and decays in a powerful series of four alpha-particle emissions. Actinium is a silvery radioactive metallic element. Actinium glows in the dark due to its intense radioactivity with a blue light. The chemical behavior of actinium is similar to that of the rare earth lanthanum. It is about 150 times as radioactive as radium.
The word actinium comes from the Greek aktis or aktinos, which means beam or ray. Actinium-225 was discovered in 1947 as part of the hitherto unknown neptunium series, which was populated by the synthesis of 233U.
Actinium-225 (225Ac) is an alpha particle-emitting radionuclide that generates 4 net alpha particle isotopes in a short decay chain to stable 209Bi, and as such can be described as an alpha particle nanogenerator.
Actinoids form the bottommost row of the periodic table. They include fifteen elements starting from Actinium (Ac) which include Americanum and Californium that are in your home smoke detectors producing an invisible radiation inside your home every day. LINK, LINK, LINK (under applications)
The radioactive decay chain ultimately converts the actinium-225 into bismuth-209. It is part of the neptunium series, for it arises as a decay product of neptunium-237 and its daughters such as uranium-233 and thorium-229. Another drawback to using Actinium-225 is not found in nature-almost completely synthetic-in compliance with the UN mandate, “nothing from nature.” It is also difficult to produce, requiring a proton accelerator and a sophisticated separation process consequently the cost of treatment will be extremely high.
Alpha radiation kills only in its immediate vicinity, so the emission source must be adjacent to the cells that need killing and if that is the whole body, then so be it.
The delivery system is an antibody: a biomolecule that latches onto a particular complementary biomolecule, found on the outside of the target cell, with great precision. Another hint that this may be more weapon than treatment is that scientists identify deliver antibodies using computer analysis and wet lab benchwork using hazardous materials. Knowing the proclivity for weaponized language, one might believe it to be another wet work, is a euphemism for murder or assassination that alludes to spilling blood.
The third last part of the triad is a stable chelator, or linking molecule, to join the actinium to the antibody. It must have a particular set of qualifications.as well as be scalable to other antibodies to treat many other pathogens.
The team of chemists, physicists, and bioscientists at Los Alamos have successfully attached Y. pestis antibody, actinium-225 and a chelator. Los Alamos and Lawrence Berkeley national laboratories have begun testing different aspects of the treatment.
To find and kill dangerous pathogens (blue) within the body, an antibody (purple) that selectively binds to an antigen on the surface of the pathogen is linked to a chelator molecule (orange) designed to carry ions of a radioactive isotope with a brief half-life. Concentrated radiation from the attached isotope delivers a lethal dose to the pathogen.
Some antibodies can cross-react with tissue and damage it.
Alpha particles are more effective at breaking DNA strands.
225Ac can be produced in spallation reactions on a 232Th target irradiated with high-energy proton beams therefore can be used with precision in a remote Direct Energy Weapon System to interact with installed techno-medical operating platforms and systems for biological life management.
Contamination with the longer-lived beta-emitting actinium-227.
It is estimated that the current supply of 225Ac only allows about a thousand treatments per year.
Actinium-227 is extremely radioactive, and in terms of its potential for radiation induced health effects, actinium-227 is about as dangerous as plutonium.
The greatest threat of radioactivity to life as we know it is damage to the gene pool, the genetic make-up of all living species.
The most extreme outcome over time would be simply the wholesale cessation of the ability to reproduce. Radiation is a known cause of sterility.
Even low-dose exposures are carcinogenic after extended exposure.
Radiation crosses species and concentrates through the food chain, subjecting other animals and humans to its damaging effects.
Actinium-227 is extremely radioactive. Radioactivity damages the gene pool not only of humans, but of all living creatures, causing cancers, immune system damage, leukemia, miscarriages, stillbirths, deformities, and fertility problems.
They have relatively high density and plasticity. Some of them can be cut with a knife.
All actinoids are radioactive, paramagnetic with the exception of actinium, have several crystalline phases.
All actinoids are pyrophoric, especially when finely divided, that is, they spontaneously ignite upon reaction with air.
Together with radium and transuranic elements, actinium is one of the most dangerous radioactive poisons. The real danger with the actinoid elements lies in the radioactive properties of these elements. They are emitters of tissue-destroying and cancer producing rays (alpha, beta, or gamma radioactivity). Actinium can accumulate and remain in the surface layer of skeletons. Less than one-millionth of a gram of some actinoid isotope can be fatal.
Actinide is mostly used in nuclear weapons.
Until the Medical Industrial Complex began to use it actinium had no commercial use. If you recall, aluminum had no commercial use but was a by-product until an entrepreneur decided to attach value to it and sell it.
Much work needs to be conducted before this treatment will become “safe and effective” in human beings and, if so, to develop it into a properly sanctioned medical treatment. But as we discovered with the COVID treatment, what was told to the public as safe and effective, was merely a play on words for human disruption and a depopulation tool, which was conveniently left out.
Heads up, with the SARSCoVid2 HIV inserts now manifesting and the insertion of radiation into monoclonal antibodies, you best check if your monoclonal antibodies not only contain humanized mice, and may now include radioactive isotopes.
None of us know when the transition from traditional antibiotics using the stealth radioactive payload treatment will occur, so prepare your decision now as to how you will handle this eventuality.
Celeste Solum is a broadcaster, author, former government, organic farmer and is trained in nursing and environmental medicine. Celeste chronicles the space and earth conditions that trigger the rise and fall of modern & ancient civilizations, calendars, and volatile economies. Cycles are converging, all pointing to a cataclysmic period between 2020 to 2050 in what many scientists believe is an Extinction Level Event.
Tracking goods and people will be a part of managing the population during this convergence.
Backstories on tracking
- Diseases, Testing, Vaccinations, and Sensors (including nCov and the new Phytophthora ~the plant-destroyer
GenSix, Keynote Speaker, True Legends, Ancient Cataclysms & Coming Catastrophes
Videos: Celestial Report, Special Broadcasts, Breaking News by Subscription
The key to making this treatment effective is threefold. “First, you need a suitable radioisotope to emit sufficient radiation—and then become inert before it does too much collateral damage,” says Kozimor. “Then you need a delivery system that will rapidly home in on the bacteria in question. Finally, you need a chemical mechanism to attach one to the other.”
The first two legs of this triad are already major Los Alamos capabilities. The Lab’s history with nuclear science and engineering has led it to develop many critical technologies, including the production of radioisotopes for medical therapies. Actinium-225, in particular, has shown tremendous promise for this type of treatment. It has a brief ten-day half-life, so it doesn’t present a long-term danger to the patient, and it decays in a powerful series of four alpha-particle emissions—a type of radiation that doesn’t penetrate far and thus is only dangerous in a very narrow radius around its target. The radioactive decay chain ultimately converts the actinium-225 into bismuth-209, which is neither radioactive nor toxic at the levels in question. Actinium-225 is not found in nature due to its short half-life and is difficult to produce, requiring a proton accelerator and a sophisticated separation process; fortunately, the Lab has both.
Alpha radiation kills only in its immediate vicinity, so the emission source must be adjacent to the cells that need killing.
The second leg, delivering the isotope to the pathogen, is another major Los Alamos success story. The delivery system is an antibody: a biomolecule that latches onto a particular complementary biomolecule, or antigen, found on the outside of the target cell, with great specificity, like lock and key. Laboratory bioscientists have developed a highly successful system for rapidly identifying specialized antibodies using a blend of computer analysis and wet-lab benchwork. One of their major antibody design efforts, for example, targets Yersinia pestis, the bacterium that causes plague, and this is the antibody Kozimor’s team used in their experiments. (Plague is treatable with existing antibiotics if caught early and not antibiotic resistant, but Y. pestis was chosen for this research to explore treatments against a germ-warfare attack. The researchers are working with its vaccine strain.)
The third and final leg is the creation of a stable chelator, or linking molecule, to join the actinium to the antibody. It must bind in a fashion that introduces no toxicity, is not simply excreted out of the patient, and is not vulnerable to having the actinium displaced by other metals found inside the body. In addition, the chelator should be designed in such a way that the methods used to create it can be easily adapted for other antibodies meant to treat other pathogens.
Kozimor leads a team of chemists, physicists, and bioscientists in the development and testing of an extraordinarily accurate Y. pestis antibody, attached to a few ions of actinium-225 via chelators, in a configuration that is therapeutically effective. Kozimor has been working through a series of increasingly effective chelators—and chelator design and analysis tools—while his Los Alamos colleague Armand Dichosa leads the biological efforts, including those by Lab scientist Antonietta Lillo to create and screen new antibodies for increasing specificity to Y. pestis—even when radiolabeled—while still maintaining sufficiently broad coverage across different Y. pestis strains. Meanwhile, other colleagues at Los Alamos and Lawrence Berkeley national laboratories have begun testing different aspects of the treatment.
At Los Alamos, scientists Jennifer Harris and Laura Lilley have been examining the effectiveness of radioisotope treatment for Y. pestis infections in human lung tissue, where the pathogen can cause pneumonic plague (as contrasted with bubonic plague, in which the pathogen is introduced through the skin, as from a flea bite). With pneumonic plague, antibiotic treatments are effective only if begun within 24 hours of the onset of symptoms, after which a radioisotope therapy could be a lifesaver. Harris and Lilley applied antibodies and isotopes to a suite of lung cells of different kinds, such as those involved in protecting the airway or oxygenating the blood. Their findings to date are quite promising.
“First off,” says Harris, “our antibodies were not harmful to the lung tissues, which is reassuring, given that some antibodies can cross-react with tissue and damage it. But more than that, at radiation levels necessary to kill bacteria or stunt its growth, we found that mature, differentiated tissues—as found in actual human lungs—were much more stable after isotope exposure than the immature cells more commonly used in research. I consider this a serious win.”
The range of expertise needed to bring something like this together is truly expansive.
Meanwhile, at the University of California, Berkeley, and Lawrence Berkeley National Laboratory, collaborator and professor Rebecca Abergel is testing the treatment paradigm on mice, as well as in the petri dish. She is working with the whole package—Los Alamos’s targeted Y. pestis antibodies chelated with actinium-225—and preliminary results are extraordinarily encouraging. The petri-dish experiments on bacterial cultures reveal that delivering the actinium via antibody greatly diminishes bacterial survival, and the experiments in mice show reduced bacterial colonization in major organs. Much remains to be done to see if this approach will be safe and effective in human beings and, if so, to develop it into a properly sanctioned medical treatment. But as initial indicators go, these present about as much success as could be hoped for.
“This is a real chance to save lives, against a backdrop of increasing rates of drug-resistant bacterial infections,” says Kozimor. “But the range of expertise needed to bring something like this together—nuclear physics and manufacturing isotopes, exquisite antibody design, chelation chemistry, biomedical testing—is truly expansive. Where do you get this kind of varied expertise all in one place for the sake of safeguarding lives? To my thinking, this is exactly what our national labs are for.”